Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065245 · ClinicalTrials.gov registry record · Phase 1
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
A Phase 1 study, sponsored by Longeveron.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02065245 is a Phase 1 study that has completed, run by Longeveron. The registered enrollment target is 65 participants.
The verdict
NCT02065245, a Phase 1 study, has completed, sponsored by Longeveron.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- BIOLOGICAL Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-03-03 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065245
The ClinicalTrials.gov registry entry for NCT02065245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longeveron, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02065245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02065245 about?
NCT02065245 is a clinical study titled "AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery". The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
What is the current status of trial NCT02065245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2014-03-03. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT02065245?
The interventions under investigation include: Placebo (BIOLOGICAL), Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) (BIOLOGICAL), Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02065245?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.